Comparison between levels of anti-HBS with a fixed administration dose of HBIG and a combination of HBIG and lamivudine for the prophylaxis of hepatitis B after liver transplantation.
Sousa
J M
JM
Hepatic Transplantation Unit, Virgen del Rocío University Hospital, Seville, Spain. jmsousa70@hotmail.com
Pareja
F
F
Serrano
J
J
Gómez
M A
MA
García
I
I
Tamayo
M J
MJ
Díaz
C
C
Martín
C
C
Pascasio
J M
JM
Hinojosa
R
R
Pérez-Bernal
J B
JB
Cañas
E
E
Sayago
M
M
Bernardos
A
A
D000328:Adult; D000368:Aged; D000914:Antibodies, Viral / Q000097:blood*; D000998:Antiviral Agents / Q000627:therapeutic use*; D006509:Hepatitis B / Q000517:prevention & control*; D006514:Hepatitis B Surface Antigens / Q000276:immunology*; D006515:Hepatitis B virus / Q000276:immunology*; D006801:Humans; D007136:Immunoglobulins / Q000627:therapeutic use*; D019259:Lamivudine / Q000627:therapeutic use*; D016031:Liver Transplantation / Q000009:adverse effects*; D008875:Middle Aged; D011183:Postoperative Complications / Q000517:prevention & control / Q000821:virology; D012008:Recurrence; D012189:Retrospective Studies
D000914:Antibodies, Viral; D000998:Antiviral Agents; D006514:Hepatitis B Surface Antigens; D007136:Immunoglobulins; D019259:Lamivudine; C045213:hepatitis B hyperimmune globulin